NNNN· Health Care› Medical Instruments & Supplies

Anbio Biotechnology Class A

Stage 4 · Declining · week 18

As of Oct 22, 2026, Anbio Biotechnology is in Stage 4, the downtrend phase, now in week 18 (since Jun 22, 2026). It closed at $3.71, 91.0% below its 52-week high and below its 200-day average, which is falling.

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. More about the company

$3.71

-0.27% today

$163M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NNNN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-02-19 → 2026-10-22

S? 41w

S2 7w

S4 9w

S1 8w

S4 18w

2025-02-192026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S3 4w → S2 7w → S1 1w → S4 9w → S1 8w → S4 18w current

Total tracked: 87 weeks across 7 stage runs.

NNNN among Medical Instruments & Supplies46th of 51 by relative strength

All 51 →

Stocks in Medical Instruments & Supplies ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	PLSEPulse Biosciences, Inc	Stage 2 · wk 34	98	+1.3%
2	PDEXPro-Dex, Inc.	Stage 2 · wk 36	97	−13.3%
3	HBIOHarvard Bioscience, Inc.	Stage 2 · wk 11	95	+3.6%
4	ATRCAtriCure, Inc.	Stage 2 · wk 10	89	−1.1%
5	WSTWest Pharmaceutical Services, Inc.	Stage 2 · wk 24	82	+4.8%
6	BDXBecton, Dickinson and Company	Stage 2 · wk 11	81	+9.8%
7	ICUIICU Medical, Inc.	Stage 3 · wk 1	81	+3.1%
8	OSUROraSure Technologies, Inc.	Stage 3 · wk 8	75	−4.8%
…46	NNNNAnbio Biotechnology Class A	Stage 4 · wk 18	8	−38.8%

vs 52W High

-91.0%

$3.13 lo$41.11 hi

91.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 18

1w13w26w

Week 18, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-79.7%

200 DMA: $18.31 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.15x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-38.8%

-62.5%

-86.4%

YTD

-87.4%

-88.0%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 18 · Vol 0.15x

2026-10-21S4

Wk 18 · Vol 0.62x

2026-10-20S4

Wk 17 · Vol 1.34x

2026-10-19S4

Wk 17 · Vol 0.31x

2026-10-16S4

Wk 17 · Vol 0.22x

2026-10-15S4

Wk 17 · Vol 0.40x

2026-10-14S4

Wk 17 · Vol 0.17x

2026-10-13S4

Wk 16 · Vol 0.26x

2026-10-12S4

Wk 16 · Vol 0.14x

2026-10-09S4

Wk 16 · Vol 0.39x

2026-10-08S4

Wk 16 · Vol 0.19x

2026-10-07S4

Wk 16 · Vol 0.20x

Moving averages & range

50 DMA

$6.04

200 DMA

$18.31

52W High

$41.11

52W Low

$3.13

5D Low

$3.13

Resistance levels (recent highs)

20d High

$6.30

60d High

$10.75

120d High

$34.44

250d High

$41.11

Next resistance

+69.8%

to 20d High

P/E (TTM)

24.7

Forward —

ROE

+27.0%

Profit margin +74.1%

Dividend Yield

0.00%

P/B 5.4

Anbio Biotechnology: quick answers

What stage is Anbio Biotechnology in?

As of Oct 22, 2026, Anbio Biotechnology (NNNN) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 22, 2026 and is in week 18. What the four stages mean

Is Anbio Biotechnology in an uptrend?

No. Anbio Biotechnology is in a Stage 4 downtrend. It trades 79.7% below its 200-day average, which is falling.

How far is Anbio Biotechnology from its 52-week high?

Anbio Biotechnology closed at $3.71 on Oct 22, 2026, 91.0% below its 52-week high of $41.11. Its 52-week low is $3.13.

How has Anbio Biotechnology performed over the past year?

As of Oct 22, 2026, Anbio Biotechnology is down 88.0% over the past year and down 87.4% so far in 2026.

Which sector and industry is Anbio Biotechnology in?

Anbio Biotechnology is in the Medical Instruments & Supplies industry, part of the Health Care sector.

About this companyHealth Care· Medical Instruments & Supplies

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.